Also known as: Bladder Bioregulator, Vesilute Khavinson Peptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Vesilute is a short peptide bioregulator from the Khavinson family, designed for urinary bladder applications. It is proposed to target bladder epithelial gene expression to support normal bladder function, reduce inflammation in chronic cystitis, and potentially address age-related bladder dysfunction including overactive bladder symptoms. The compound has been used in Russian clinical settings for chronic interstitial cystitis, recurrent urinary tract infections, and age-related urinary urgency / frequency.
Russian clinical-observational studies have evaluated Vesilute in patient populations with chronic bladder dysfunction, with reported improvements in symptom scores, frequency-volume diary measures, and quality-of-life metrics. The compound is sometimes used in combination with Prostamax in elderly male patients to address overlapping prostate / bladder dysfunction.
Vesilute is sold by research-chemical vendors outside Russia. Western clinical validation is essentially absent. As with all Khavinson bioregulators, the compound should not substitute for proper urological evaluation in patients with significant urinary symptoms, where ruling out infection, stones, malignancy, and neurological causes is essential.
Vesilute was developed in the 2000s as part of the Khavinson bioregulator program, with the bladder-targeting member of the family aimed at chronic bladder dysfunction and age-related urinary symptoms. The compound entered Russian clinical observational use through the 2000s and 2010s.
Russian clinical use has reported good tolerability in urological patient populations. Western safety validation is essentially absent. Patients with significant urinary symptoms should undergo appropriate urological workup to rule out treatable causes before relying on peptide bioregulators alone.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
~400-600 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian urology
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering the full short-peptide bioregulator family including Vesilute.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to all tissue-targeting bioregulators including Vesilute.
View Study →Khavinson VK, Morozov VG, Anisimov VN
Advances in Gerontology (2016)
Russian-group review of peptide bioregulators in urological applications, providing observational context for Vesilute and related compounds.
View Study →Khavinson short peptide bioregulator targeting prostate tissue.
Khavinson short peptide bioregulator targeting vascular endothelium — KED tripeptide.
Khavinson short peptide bioregulator targeting thymus / immune cells.
Track Vesilute and more with PinnyPeptide.
Sign Up to Track VesiluteFree forever · defaults pre-filled from this article